Quantum Biopharma (QNTM) Income from Continuing Operations (2019 - 2026)
Quantum Biopharma (QNTM) posted Income from Continuing Operations of 2989159.0 for Q1 2026, down 29.92% sequentially from 2300748.0 in Q4 2025, and up 12.67% YoY from 2653042.11 in Q1 2025.
Quantum Biopharma (QNTM) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Quantum Biopharma has reported Income from Continuing Operations for 8 years, with the latest figure at 2989159.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 12.67% year-over-year to 2989159.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 15030005.0 (up 3.64% YoY) and the FY2025 annual result came in at 26956840.0, down 80.73% from the prior year.
- Income from Continuing Operations fell to 2989159.0 in Q1 2026 per QNTM's latest filing, from 2300748.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 5630055.0 in Q1 2022 and troughed at 34809610.0 in Q4 2023.
- A 5-year average of 5608010.0 and a median of 3438192.5 in 2024 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 84.33% in 2024, down 278.05% in 2024.
- Over 5 years, Income from Continuing Operations stood at 5630055.0 in 2022, then tumbled by 718.28% to 34809610.0 in 2023, then jumped by 84.33% to 5456278.0 in 2024, then surged by 57.83% to 2300748.0 in 2025, then dropped by 29.92% to 2989159.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 2989159.0, 2300748.0, and 4769697.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Quantum Biopharma | 15.44 Mn | 11.80 Mn | - | -2.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.29 Mn |
| Mar 31, 2026 | -2.99 Mn |
| Dec 31, 2025 | -2.30 Mn |
| Sep 30, 2025 | -4.77 Mn |
| Jun 30, 2025 | -4.97 Mn |
| Mar 31, 2025 | -3.42 Mn |
| Dec 31, 2024 | -5.46 Mn |
| Sep 30, 2024 | -3.27 Mn |
| Jun 30, 2024 | -3.45 Mn |
| Mar 31, 2024 | -2.27 Mn |
| Dec 31, 2023 | -34.81 Mn |
| Sep 30, 2023 | -863,852.00 |
| Jun 30, 2023 | -5.72 Mn |
| Mar 31, 2023 | -9.85 Mn |
| Mar 31, 2022 | 5.63 Mn |
| Jun 30, 2021 | -12.71 Mn |
| Mar 31, 2021 | 9.78 Mn |
| Sep 30, 2020 | -13.18 Mn |
| Jun 30, 2020 | -3.53 Mn |
| Mar 31, 2020 | -5.06 Mn |